Use of Rapid Antigen Testing for SARS-CoV-2 in Remote Communities — Yukon-Kuskokwim Delta Region, Alaska, September 15, 2020–March 1, 2021
MMWR. Morbidity and Mortality Weekly Report·
- DOI
- 10.15585/mmwr.mm7033a3
- PMID
- 34411078
- PMCID
- PMC8375707
- OpenAlex
- W3195865288
- Study type
- Journal article
- Publisher
- Centers for Disease Control MMWR Office
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings suggest that rapid testing may improve timeliness of diagnosis in remote communities with limited local access to laboratory-based NAAT. The abstract links faster results with the practical potential for earlier isolation, contact tracing, and local mitigation activities.
Structured evidence summary
Research question
The study assessed whether introducing rapid point-of-care antigen testing in remote Yukon-Kuskokwim Delta communities was associated with faster SARS-CoV-2 result reporting and changes in reported case incidence.
Study design
This was a retrospective review of 54,981 antigen and molecular SARS-CoV-2 tests performed from September 15, 2020, through March 1, 2021, comparing periods before and after rapid antigen testing was introduced.
Population and setting
The setting was the rural Yukon-Kuskokwim Delta region of southwestern Alaska, comprising remote and isolated villages that were primarily accessible by air. The analysis covered testing conducted during September 15, 2020–March 1, 2021.
Main findings
After rapid antigen testing began, median result turnaround decreased from 6.4 to 4.4 days, a reduction exceeding 30% (p<0.001). Reported daily incidence fell from 342 to 119 cases per 100,000 population between the weeks of November 9 and December 13, 2020 (p<0.001), and the abstract describes a greater-than-threefold reduction in daily case rates during approximately the following month.
Public-health relevance
The findings suggest that rapid testing may improve timeliness of diagnosis in remote communities with limited local access to laboratory-based NAAT. The abstract links faster results with the practical potential for earlier isolation, contact tracing, and local mitigation activities.
Important limitations
The supplied abstract does not state specific study limitations. This summary is limited to a single article's abstract and metadata; the original paper is needed for decision-grade assessment of design constraints, confounding, testing changes, and interpretation of the before-and-after comparisons.
GIDS interpretation
This article is discoverable as evidence concerning SARS-CoV-2 outbreak investigation, transmission-related outcomes, and testing in remote communities. It provides article-specific context only and does not establish or confirm any current surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.